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Additional Evidence for the Existence
of a Precursor Molecule of the Prothrombin Complex
in Oral Anticoagulation
J. J. Vnr,rnaur, If. Murs, A. D. Mur,r,en, H. C. Hpuxpn and E. A. Lonr,rsnn
X"  K.  SCI IATTAUER,  VER,LAG .  STUTTGAR,T_NEWYOR,K,
In vitamin K deficiency or intake of oral anticoagulants (vitamin K-antagonists) the
s;mthesis of the blood clotting factors of the prothrombin complex is blocked in one of
its last steps. Pol;ryeptide chain synthesis on the ribosomal level (7) is not hampered,
and the demonstration of precursor prod.ucts, which hypothetically could resemble the
clotting factors, has been attempted in several investigations (2, 3, 5, 8). Immuno-
chemical methods enabled Ganrot and Nil6hn (2) to demonstrate two populations of
prothrombin molecules in coumarin plasma, and Josso et al. (8) found in excess of
immunologically demonstrable prothrombin over prothrombin activity. The present
report concerns the demonstration of a precursor molecule that resembles factor fX in
its antigenic properties.
Methods
Factor fX (PTC) assays were carried out with a one-stage kaolin-phospholipid activa.ted prin-
ciple (14). clotting times were read automatically with coagulometers (DEPEX, de Bilt, The
Netherlands). The PTC-inhibitor plasma was kindly supplied by Dr. Harold R oberts of Chapel Hill.
The inhibitor plasma was received on 27 Jrly 1969 and stored at - 80o C. It was used in a dilution
of 1:2 in the method for measuring PTO-inhibitor neutralizing capacity as deseribed by Roberts
ei al. (1, 12), The titre of the inhibitor did not alter during more fhan a year of storage.
Results
rn Table 1 it can be seen that a coumarin plasma, in this case obtained from a pa-
tient (No.7) with virtually no factor IX activity in the plasma due to suicidal intake of
the long-acting coumarin-congener phenprocoumon, contains a large amount of PTC-
inhibitor neutralizing material. This particular plasma also had less than Lo/ofactorlI,
vrr, and X activity. Another patient (No.8), with 8.5% factor rX activity (Thrombo-
test 300 sec due to overdosage oi phenprocoumon), showed 22% PTC-INC (PTC
.Inhibitor -lfleutralizing Capacity). BaSoo adsorption removes not only "clottable"
factor rX (No.11) but also PTC-rNC (No.10) from oxalated plasma. al(oH)s has the
same action on citrated plasma. PTC-INC is not mimickeil by the presence of phenpro-
coumon, as can be judged from the result obtained with plasma No. 12, which rvas
composed of sample No.6 to which phenprocoumon was added in uitro in a concen-
tration of 10 pgiml. This concentration is comparable to the concentration of the
coumarin-congener in samples 7 and 8 (about 7 lt"glml), assayed according to Seiler
and Duckert (13).
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Table 1. PTC-inhibitor neutralizing capacity (PTC-INC) of various plasma samples.
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PTC.INC
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factor IX
r in o/o)
Number
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More
PTC-INC
than
factor IX
activity
1, Normal plasma
2. Diluted normal plasma
3. Diluted normal plasma
4. Buffer
5. By-plasma
6. B-plasma
7. Coumarin plasma
8. Coumarin plasma
9. Citrated couma,rin plasma
Al(OH), adsorbed
10, Oxalated coumarin plasma
BaSOn adsorbed
11. Normal oxalated plasma
BaSOn adsorbed
12. B-plasma, f phenprocoumon
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Discussion
Oral anticoagulants take effect not only by depressing coagulation factors II, VII,
IX, and X, due to an anti-vitamin-K action, but also cause the appearance of a pro-
tein called PIVKA (Protein lnduced by Zitamin K,4bsence) (5). In prothrombin
time methods using thromboplastins prepared from brain from various species (9),
this protein exerts a competitive inhibitory effect. The site of inhibition in the reaction
sequence of coagulation has been localized at the conversion of factor X from a pro-
enzyme into an active moiety (4).
It is thought that the protein in question is a precursor of one or mor€; of the coagu-
lation factors of the prothrombin complex. During the blockade of the vitamin-K-
dependent step assumed to be responsible for conversion of the precursor into a coagu-
lation factor (II, VII, IX, or X), sS,rrthesis of the precursor in hepatic cells leads to
overflow of the precursor into the circulation. On the basis of this hlpothesis coagula-
tion-factor like protein could be expected to circulate in vitamin-K-deficiency or oral
anticoagulation. In attempting to further define the precursor, Ganrot and Nil6hn (2)
demonstrated a prothrombin in coumarin plasma with a electrophoretic mobility
differing from the normal. They also reported defective adsorption of PIVKA onto
BaSOn, but this finding seems doubtful, because they used citrated plasma and adsorb-
ecl urith 10 mg BaSOoiml. Under these conditions, the adsorption of both the pro-
thrombin complex and PIVKA is known to be incomplete.
Another indication of the presence of a prothrombin-like material in anticoagulated
human plasma is the finding of material that develops thrombin activity at a rate
much more slowly than prothrombin itself (6). Investigations by both Prentice (10)
and Prydz (11) clearly demonstrated an excess of immunologically detectable factor X
over factor X activity in anticoagulated samples.
3r4
The investigation reported here shorvs that a signiflcant amount of PTC-inhibitor
neutralizing material can be demonstrated in anticoagulated human plasma. The few
selected samples used in this study contain very low factor IX activity and thus
enabled us to make economic use of the PTC-inhibitor. Hisher levels of factor IX
activity make the interpretation of the difference from the residual factor IX activity
reflecting the amount of PTC-inhibitor neutralizing material progressively more dif-
ficult (and therefore create a statistical problem).
The existence of protein induced by vitamin K absence or antagonist has been
demonstrated in different ways: as an in-h.ibitor of prothrombin time t;rye estimation,
as an abnormal prothrombin, as anti-factor-Il cross-reacting material, as antiJactor-X
cross-reacting material, and, now as PTO-inhibitor neutralizing capacity. We do not
as yet want to assume the existence of a different precursor for each of the vitamin K
dependent coagulation factors, because the activities mentioned might all be due to a
single type of molecule. The possibility that more than one t5rye of PIVKA exists must,
be taken into consideration.
Summary
By means of the PTO-inhibitor neutralizing test (12) a significant excess of PTC
(factor IX)-like material over factor IX activity could be demonstrated in human
coumarin plasma. This cross-reacting material is considered to be a precursor of one
or all of the clotting factors of the prothrombin complex.
R6sum6
A l'aide du test de neutralisation du PTC (12) on met en 6vidence, dans le plasma
d'individus trait6s aux d6riv6s de la coumarine, un excds marqu6 de mat6riel sem-
blable au PTC (facteur IX) par rapport au facteur IX procoagulant. Ce mat6riel inter-
f.6ranl est consid6r6 comme 6tant un pr6curseur d'un ou de tous les facteurs du com-
plexe de la prothrombine.
Zusammenfassung
Mit Hilfe des PTC-Inhibitorneutralisationstestes (12) konnte im menschlichen
Coumarin-Plasma ein signifikanter UberschuB an PT0-(n'aktor IX)-ri,hnlichem Mate-
rial gegeniiber der Gerinnungsfaktor-IX-Aktivitti,t nachgewiesen werden. Es wird an-
genommen, daB dieses kreuzreagierende Material eine Vorstu{e eines oder aller Gerin-
nungsfaktoren des Prothrombinkomplexes ist.
References
(1)  Brown,P.E.,C.Hougi ,e,H.R.Roberts:Ahegonet ichoterogenei tyofhemophi l iaB.NewEngl .
J.  Med. 283:6r-62 (1970).
(2) Ganrot, P.O.,J.E.Nildhm:Plasrna,prothrombinduringtreatmentwithdicumarolll:Domon.
stration of an abnormal prothrombin fraction. Scand. J. clin. Lab. Invesf, 2P: ZB (1968).
(3) Hem,ker, H. C., J. J. Veltkamp, A. Hensem, E. A. Loel,iger: Nature of prothrombin biosSzrthe-
sis : Preprothrombinaemia in vitamin I(-deficiency. Nature (Lond. ) 200 : E8g (lg68).
(4) Hemker, H. C., A. D. Muller: Ilinetic aspects of the interaction of blood clotting enzymes V.
The reaction mochanism of the extrinsic coagulation systom as revealed by tho kinetics of one-
stage estimations of coagulation enz5rmes. Thrombos. Diathes. haomorrh. (Stuttg.) 19: 368
(1e68 ) .
l
I
315
(5) Eemlcer, H' V., J. J. Veltkamyt, E. A, Loeldger..Kinetic aspects of tho intora,otion of bloodenzJznes' rrr. The roaction mochanism of tho. extringic clolting system 
"" ";;";i;Jl;;;kinetics of one-stage estimations of coagulation enzJrrnes. rlio-ro*. Diathos. haemorrh.(Stuttg.) 
-r9; 346 (1968).
(6) Hemker, E. c., a. D. Muuer, E. A. Loeri,ger..preriminary reports: Two ty?es of prothrombinin vitamin K-deficiency. Thrombos. Diathos. haemorrh. (stuttg.) zJ; 688-688 (1970).' (7) rrdll' R. 8., B. Gaetamd, A. M. paolwcci, p. B. Ranoafuao, n. liain,G, B. Ranhotra..vitamin r(
.^. lndbio:rnthesisofproteinandprothrombin.J.biol. chern.z43:BgB0(1968).(8) Josso, r,, J, M. Louergne, M. Gouaurt, o. prow-walterte, J. p. sowri,er': Differents 6tats mole-culaires du facteur rI (prothrombine). Leur 6tude a, I'aide de t* *i*frryio"o"golase et d,anti-
oorps anti-facteur rr. r. Le facf,eur Ir chez los sujets trait6s par lJs i,ntagonlstes de la vit-amino K. Thrombos. Diathes. haemorrh. (Stuttg.) Z0; gg (1968).(9) Loel'i1ier, E. a., J. B. Meewu,isse-Brawn, H. Muis, F.'J. J. Bugtendijra, J. J. vettrcam?t,H'C'Hemlcer: Laboratorycontrolof oralanticoagulants: Definitiooof it""upuoir" 
"""g;"iriterms of differont thromboplastin preparations. Thrombos. Diathos. haemorrh. (Stuttg.) 2Jr569 (1e70).
(10) Prentdce' c' ll4'.'Panel discussion. Tho rnbrna0ional Society on Thrombosis and rlaomostasis.Montreux, Switzerlaod, July 2g -August 1, 1920.(ll) Pryd'2, r/..' Panol discusqion. The rnternational Socioty on Thrombosis and rraemostasis.Montreux, Switzerland, July 2g - August 1, 1970.(12) Roberie' H. E.' J- E. Grdzzre, w. D. MaLester eb a,r.z Genotic variants of hemophilia B:dotection by means of e specific prc inhibitor. J. crin, rnvesf. 42.. 960-865 (r96s).(13) seiler' K., E. Du,okert: Properties of 3-(1-phenyl-propyl)-4-oxycoumarin (Marcoumar@) in theplasma when tesbed in normal 
"ruu" "rrd. ""au" trru irrhouo"L of drugs.'Th"o-bou. Diathes.haomorrh. (Stuttg.) -29.. 989-997 (1968).(14) veltl&mp' J. J.' F- F' Drion, E. A. Loeliger.'Dotection of the carrier stato in heroditary
coagulation disorders. r. Thrombos. Diathes. haemorrh. 19:279 (196g); rr. Thrombos. Dia_thes. ha,omomh. I9..408 (1963).
Received for Publication Z. lZ. lgTO
copyright bv F. K. sdattauer v_erlag_,_stuttgart - Der verlag behiilt sid alle Redrte, besonders die des Na&dru&es,der Vervielfiltigung und der Ubcrseuung vor.
I
